in vivo evaluations of 18 F-AV-1451 in patients with pathological confirmation.
We report a multimodal evaluation of a 58-year-old male with autopsy-confirmed CBD. He participated in in vivo baseline (15 months pre-death) clinical, 18 F-AV-1451 PET, 18 F-florbetapir PET, MRI, and DTI and longitudinal (5 months pre-death) 18 F-AV-1451 PET research studies (Online Resource 1). When enrolled in research, the patient met clinical criteria for progressive supranuclear palsy (Online Resource 2).
Baseline 18 F-AV-1451 (Fig. 1a) revealed the highest retention in deep grey matter areas commonly associated with CBD pathology [1] , including bilateral substantia nigra, globus pallidus, and midbrain. Follow-up 18 F-AV-1451 revealed more visible retention in bilateral frontal and posterior temporal cortical regions along with midbrain and pons (Fig. 1b) . A direct assessment of annualized change revealed a 1-9 % increase in 18 F-AV-1451 retention, which was highest in the pons, medulla, and midbrain along with bilateral frontal and right temporo-parietal cortices (Fig. 1c) .
Baseline MRI (Fig. 2a) revealed predominantly reduced cortical grey matter in bilateral frontal cortex and right angular gyrus along with deep grey structures, including the midbrain, putamen, right globus pallidus, right caudate, and left hippocampus. White matter revealed increased mean diffusivity (a measure of white matter integrity) in the corpus callosum, bilateral tapetum, pontine crossing fibres, and right lateralized corticospinal tract, and posterior corona radiata. These observations are consistent with previously reported distributions of disease in CBD [6] . Spearman correlations revealed inverse associations between baseline 18 F-AV-1451 and grey matter volume (r s = −0.209; p = 0.016; Fig. 2b ) and mean diffusivity (r s = −0.329; p = 0.032; Fig. 2c ). Furthermore, we Corticobasal degeneration (CBD) is characterized by 4-repeat misfolded tau (4Rtau) including astrocytic plaques, threads, and neuronal tangles [1] .
18 F-AV-1451 is a PET radioligand that achieves in vivo binding in Alzheimer's disease (AD) [8] and autoradiographic evidence of binding to paired helical filaments (PHFs) composed of 3-repeat misfolded tau (3Rtau) and 4Rtau characteristic of AD histopathology [4, 5, 7] . However, autoradiographic studies of 18 F-AV-1451 on CBD postmortem tissue failed to demonstrate binding in cortical regions [5, 7] , though there was minimal pathology in one study (<1.1 % tau-load) [7] . Another study suggests minimal, but present, autoradiographic binding of 18 F-AV-1451 for 4Rtau [4] . Given mixed autoradiographic evidence in CBD, there is a need for Neuropathological examination including immunohistochemistry (IHC) for phosphorylated tau and tau-isoformspecific antibodies confirmed a diagnosis of CBD and Western blot analyses confirmed 4Rtau pathology ( Fig. 2d ; Online Resource 4). A Spearman correlation revealed that the percent area occupied (%AO) by tau was related to follow-up 18 F-AV-1451 SUVR (r s = 0.768; p = 0.001; Fig. 2e ). Moreover, a 18 F-AV-1451 SUVR ≥1.2 (high retention) captured all seven regions with high tau pathology (%AO ≥5.0) and did not capture any regions with low tau pathology (%AO <5.0). Using this pathologically defined cutoff (SUVR ≥1.2), we also observed more deep grey matter and white matter atrophy in regions above the cutoff relative to those below the cutoff (Online Resource 5). While we did not observe a correlation between annualized 18 F-AV-1451 change and %AO of tau (r s = −0.308; p = 0.246), 6/7 regions with %AO ≥5.0 of tau exhibited an increase in annualized 18 F-AV-1451 retention (0.7-7.2 %) (Online Resource 3). Prior studies have suggested that 8 F-AV-1451 may have "off-target" binding to pigmented cells [5] . In this patient, the vast majority of melanin-containing cells in the substantia nigra were tau positive, and therefore 18 F-AV-1451 retention associated with reduced b grey matter volume and c white matter integrity; d heatmap reflecting ordinal ratings of PHF-1 tau burden rated as severe (3+; red) in midbrain (MB), pons (PON), substantia nigra (SN), globus pallidus (GP), putamen (CP), and amygdala (AMY); moderate rating (2+; orange) in thalamus (THAL), medulla (M), and CA1/subiculum (HIPca) along with anterior cingulate (ACC), middle frontal (MFC), entorhinal (HIPec), angular gyrus (AGC), and superior temporal (STC) cortices; mild scattered tangles (1+; yellow) in the cerebellum (CB); and no pathology in the primary visual cortex (PVC); e correlation between AT-8 percent area occupied and follow-up (5 months pre-death) 18 F-AV-1451 retention it was not possible to discriminate between "off-target" or "pathological" 18 F-AV-1451 retention. Potential differences in 18 F-AV-1451 retention between AD and CBD may reflect different structures of the tau filaments, which are tubular or straight filaments in CBD and not PHFs as in AD [1] . An autoradiographic study of 18 F-AV-1451 in AD observed more binding to neurofibrillary tangles than neuritic tau pathology [4] . We evaluated differential affinity for the tangle and thread pathological features of CBD [1, 2] and observed that 18 F-AV-1451 uptake was more highly related to thread (r s = 0.712; p = 0.004) than tangle (r s = 0.630; p = 0.022) pathology. Future studies must assess the mechanisms for possible differential affinity of 18 F-AV-1451 for various forms of tau pathology. This multimodal assessment provides suggestive evidence that in vivo PET imaging with 18 F-AV-1451 correlates with 4Rtau, including threads and plaques that are presumably glial in origin [1] . Additionally, 18 F-AV-1451 retention is related to MRI and DTI at baseline and appears to increase over the disease course in brain regions containing 4Rtau pathological burden. These findings converge with other postmortem evidence of 18 F-AV-1451 retention in MAPT mutation carriers [9] and a patient with CBD [3] . However, single case data should be interpreted cautiously and future cohort studies, additional autoradiography studies, and direct comparisons between CBD and AD are necessary to validate 18 F-AV-1451 imaging for 4Rtau in CBD.
